IN2014DN06166A - - Google Patents
Info
- Publication number
- IN2014DN06166A IN2014DN06166A IN6166DEN2014A IN2014DN06166A IN 2014DN06166 A IN2014DN06166 A IN 2014DN06166A IN 6166DEN2014 A IN6166DEN2014 A IN 6166DEN2014A IN 2014DN06166 A IN2014DN06166 A IN 2014DN06166A
- Authority
- IN
- India
- Prior art keywords
- salts
- compositions
- methods
- tricyclic compounds
- fused tricyclic
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5365—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines ortho- or peri-condensed with heterocyclic ring systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A61K31/52—Purines, e.g. adenine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D473/00—Heterocyclic compounds containing purine ring systems
- C07D473/26—Heterocyclic compounds containing purine ring systems with an oxygen, sulphur, or nitrogen atom directly attached in position 2 or 6, but not in both
- C07D473/28—Oxygen atom
- C07D473/30—Oxygen atom attached in position 6, e.g. hypoxanthine
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
- C07D519/02—Ergot alkaloids of the cyclic peptide type
Abstract
Provided are certain fused tricyclic compounds and salts thereof compositions thereof and methods of use therefor.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
PCT/CN2011/085146 WO2013097224A1 (en) | 2011-12-31 | 2011-12-31 | Fused tricyclic compounds as raf kinase inhibitors |
Publications (1)
Publication Number | Publication Date |
---|---|
IN2014DN06166A true IN2014DN06166A (en) | 2015-08-21 |
Family
ID=48696279
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
IN6166DEN2014 IN2014DN06166A (en) | 2011-12-31 | 2011-12-31 |
Country Status (29)
Country | Link |
---|---|
US (3) | US9273046B2 (en) |
EP (2) | EP3124472B1 (en) |
JP (1) | JP5868521B2 (en) |
KR (1) | KR101713391B1 (en) |
CN (1) | CN103596926B (en) |
AU (1) | AU2011384857B2 (en) |
BR (1) | BR112014013108B1 (en) |
CA (1) | CA2856347C (en) |
CY (1) | CY1118226T1 (en) |
DK (1) | DK2797888T3 (en) |
EA (1) | EA025597B1 (en) |
ES (1) | ES2588775T3 (en) |
HK (2) | HK1192232A1 (en) |
HR (1) | HRP20160641T1 (en) |
HU (1) | HUE029656T2 (en) |
IL (1) | IL233364A (en) |
IN (1) | IN2014DN06166A (en) |
LT (1) | LT2797888T (en) |
ME (1) | ME02529B (en) |
MX (1) | MX352617B (en) |
NZ (1) | NZ624068A (en) |
PL (1) | PL2797888T3 (en) |
PT (1) | PT2797888T (en) |
RS (1) | RS55196B1 (en) |
SG (1) | SG11201401725SA (en) |
SI (1) | SI2797888T1 (en) |
SM (1) | SMT201600302B (en) |
WO (1) | WO2013097224A1 (en) |
ZA (1) | ZA201405555B (en) |
Families Citing this family (19)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
HUE029656T2 (en) | 2011-12-31 | 2017-03-28 | Beigene Ltd | Fused tricyclic compounds as raf kinase inhibitors |
NZ716392A (en) | 2013-06-28 | 2017-03-31 | Beigene Ltd | Fused tricyclic urea compounds as raf kinase and/or raf kinase dimer inhibitors |
JP6380862B2 (en) * | 2013-06-28 | 2018-08-29 | ベイジーン リミテッド | Condensed tricyclic amide compounds as inhibitors of multiple kinases |
WO2015089809A1 (en) * | 2013-12-19 | 2015-06-25 | Merck Sharp & Dohme Corp. | Antidiabetic substituted heteroaryl compounds |
WO2015176267A1 (en) * | 2014-05-22 | 2015-11-26 | Merck Sharp & Dohme Corp. | Antidiabetic tricyclic compounds |
GB201416186D0 (en) * | 2014-09-12 | 2014-10-29 | Redx Pharma Ltd | Compounds |
JP7320741B2 (en) | 2015-04-15 | 2023-08-04 | ベイジーン リミテッド | Maleate salts of B-RAF kinase, crystal forms, methods of preparation, and uses thereof |
JP6175519B2 (en) * | 2016-01-04 | 2017-08-09 | ベイジーン リミテッド | Condensed tricyclic compounds as Raf kinase inhibitors |
AU2017293423B2 (en) * | 2016-07-05 | 2023-05-25 | Beigene, Ltd. | Combination of a PD-1 antagonist and a RAF inhibitor for treating cancer |
AU2017366693B2 (en) | 2016-12-01 | 2021-04-01 | Arvinas Operations, Inc. | Tetrahydronaphthalene and tetrahydroisoquinoline derivatives as estrogen receptor degraders |
IL294423B2 (en) * | 2016-12-23 | 2024-01-01 | Univ Yale | Compounds and methods for the targeted degradation of rapidly accelerated fibrosarcoma polypeptides |
US11173211B2 (en) | 2016-12-23 | 2021-11-16 | Arvinas Operations, Inc. | Compounds and methods for the targeted degradation of rapidly accelerated Fibrosarcoma polypeptides |
JP2022500385A (en) | 2018-09-10 | 2022-01-04 | ミラティ セラピューティクス, インコーポレイテッド | Combination therapy |
CN111184693B (en) * | 2019-05-29 | 2023-07-21 | 百济神州(苏州)生物科技有限公司 | RAF kinase inhibitor preparation and preparation method thereof |
AU2020405129A1 (en) | 2019-12-19 | 2022-06-23 | Arvinas Operations, Inc. | Compounds and methods for the targeted degradation of androgen receptor |
AU2021314955A1 (en) | 2020-07-28 | 2023-03-30 | Jazz Pharmaceuticals Ireland Limited | Fused bicyclic Raf inhibitors and methods for use thereof |
WO2023049060A1 (en) * | 2021-09-21 | 2023-03-30 | Merck Sharp & Dohme Llc | Allosteric modulators of nicotinic acetylcholine receptors |
WO2023212071A1 (en) * | 2022-04-26 | 2023-11-02 | Beigene Switzerland Gmbh | Combination and the use thereof |
WO2023209611A1 (en) | 2022-04-26 | 2023-11-02 | Beigene Switzerland Gmbh | Methods of treating cancer with a b-raf inhibitor, in particular lifirafenib |
Family Cites Families (21)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU2003245700A1 (en) | 2002-02-12 | 2003-09-04 | Glaxo Group Limited | Pyrazolopyridine derivatives |
SI1696920T1 (en) | 2003-12-19 | 2015-02-27 | Plexxikon Inc. | Compounds and methods for development of ret modulators |
AU2005316668B2 (en) | 2004-12-13 | 2012-09-06 | Millennium Pharmaceuticals, Inc. | Pyrido pyrimidinones, dihydro pyrimido pyrimidinones and pteridinones useful as RAF kinase inhibitors |
CA2589779A1 (en) | 2004-12-23 | 2006-06-29 | F. Hoffmann-La Roche Ag | Benzamide substituted imidazo- and pyrolo-pyridines as protein kinase inhibitors |
TW200639163A (en) * | 2005-02-04 | 2006-11-16 | Genentech Inc | RAF inhibitor compounds and methods |
US7846941B2 (en) | 2005-05-17 | 2010-12-07 | Plexxikon, Inc. | Compounds modulating c-kit and c-fms activity and uses therefor |
JP2008540674A (en) | 2005-05-20 | 2008-11-20 | アレイ バイオファーマ、インコーポレイテッド | RAF inhibitory compounds and methods of use thereof |
PE20070100A1 (en) | 2005-06-22 | 2007-03-10 | Plexxikon Inc | PIRROLO [2,3-b] PYRIDINE DERIVATIVES AS KINE MODULATORS |
KR20080052630A (en) | 2005-09-01 | 2008-06-11 | 어레이 바이오파마 인크. | Raf inhibitor compounds and methods of use thereof |
ZA200804679B (en) * | 2005-12-08 | 2010-02-24 | Millenium Pharmaceuticals Inc | Bicyclic compounds with kinase inhibitory activity |
US7442808B2 (en) * | 2006-05-15 | 2008-10-28 | Merck & Co., Inc. | Antidiabetic bicyclic compounds |
WO2008023239A1 (en) * | 2006-08-23 | 2008-02-28 | Pfizer Products Inc. | Pyrimidone compounds as gsk-3 inhibitors |
EP2064213A1 (en) | 2006-09-06 | 2009-06-03 | F. Hoffmann-La Roche AG | Heteroaryl derivatives as protein kinase inhibitors |
EP2061761A1 (en) | 2006-09-07 | 2009-05-27 | Millennium Pharmaceuticals, Inc. | Phenethylamide derivatives with kinase inhibitory activity |
WO2008079909A1 (en) | 2006-12-21 | 2008-07-03 | Plexxikon, Inc. | Pyrrolo [2,3-b] pyridines as kinase modulators |
PE20121126A1 (en) | 2006-12-21 | 2012-08-24 | Plexxikon Inc | PIRROLO [2,3-B] PYRIDINES COMPOUNDS AS KINASE MODULATORS |
BRPI0811517A2 (en) * | 2007-05-04 | 2014-11-18 | Irm Llc | COMPOUNDS AND COMPOSITIONS AS C-KIT AND PDGFR KINASE INHIBITORS. |
US20100190777A1 (en) | 2007-07-17 | 2010-07-29 | Plexxikon Inc. | Compounds and methods for kinase modulation, and indications therefor |
US20100197924A1 (en) * | 2008-12-22 | 2010-08-05 | Millennium Pharmaceuticals, Inc. | Preparation of aminotetralin compounds |
HUE029656T2 (en) | 2011-12-31 | 2017-03-28 | Beigene Ltd | Fused tricyclic compounds as raf kinase inhibitors |
JP7320741B2 (en) | 2015-04-15 | 2023-08-04 | ベイジーン リミテッド | Maleate salts of B-RAF kinase, crystal forms, methods of preparation, and uses thereof |
-
2011
- 2011-12-31 HU HUE11879096A patent/HUE029656T2/en unknown
- 2011-12-31 MX MX2014007829A patent/MX352617B/en active IP Right Grant
- 2011-12-31 PL PL11879096.3T patent/PL2797888T3/en unknown
- 2011-12-31 WO PCT/CN2011/085146 patent/WO2013097224A1/en active Application Filing
- 2011-12-31 RS RS20160713A patent/RS55196B1/en unknown
- 2011-12-31 DK DK11879096.3T patent/DK2797888T3/en active
- 2011-12-31 PT PT118790963T patent/PT2797888T/en unknown
- 2011-12-31 CN CN201180069798.XA patent/CN103596926B/en active Active
- 2011-12-31 KR KR1020147018101A patent/KR101713391B1/en active IP Right Grant
- 2011-12-31 NZ NZ624068A patent/NZ624068A/en unknown
- 2011-12-31 BR BR112014013108-2A patent/BR112014013108B1/en active IP Right Grant
- 2011-12-31 US US14/369,379 patent/US9273046B2/en active Active
- 2011-12-31 IN IN6166DEN2014 patent/IN2014DN06166A/en unknown
- 2011-12-31 AU AU2011384857A patent/AU2011384857B2/en active Active
- 2011-12-31 ES ES11879096.3T patent/ES2588775T3/en active Active
- 2011-12-31 JP JP2014549294A patent/JP5868521B2/en active Active
- 2011-12-31 EP EP16167542.6A patent/EP3124472B1/en active Active
- 2011-12-31 SI SI201130852A patent/SI2797888T1/en unknown
- 2011-12-31 EP EP11879096.3A patent/EP2797888B1/en active Active
- 2011-12-31 CA CA2856347A patent/CA2856347C/en active Active
- 2011-12-31 EA EA201491305A patent/EA025597B1/en not_active IP Right Cessation
- 2011-12-31 ME MEP-2016-172A patent/ME02529B/en unknown
- 2011-12-31 LT LTEP11879096.3T patent/LT2797888T/en unknown
- 2011-12-31 SG SG11201401725SA patent/SG11201401725SA/en unknown
-
2014
- 2014-06-12 HK HK14105541.7A patent/HK1192232A1/en unknown
- 2014-06-25 IL IL233364A patent/IL233364A/en active IP Right Grant
- 2014-07-28 ZA ZA2014/05555A patent/ZA201405555B/en unknown
-
2016
- 2016-01-22 US US15/004,311 patent/US9895376B2/en active Active
- 2016-06-09 HR HRP20160641TT patent/HRP20160641T1/en unknown
- 2016-08-05 HK HK16109391.8A patent/HK1221222A1/en unknown
- 2016-09-05 CY CY20161100869T patent/CY1118226T1/en unknown
- 2016-09-06 SM SM201600302T patent/SMT201600302B/en unknown
-
2018
- 2018-01-29 US US15/882,064 patent/US10576087B2/en active Active
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
IN2014DN06166A (en) | ||
IN2014CN02639A (en) | ||
IN2014CN02283A (en) | ||
HK1213251A1 (en) | 3-pyrimidin-4-yl-oxazolidin-2-ones as inhibitors of mutant idh idh 3--4---2- | |
IN2012DE02913A (en) | ||
UY34836A (en) | NEW ORGANISMS | |
MX2014007840A (en) | Fused tetra or penta-cyclic dihydrodiazepinocarbazolones as parp inhibitors. | |
CO7111289A2 (en) | Metalloenzyme inhibitor compounds | |
UY33925A (en) | TRICYCLIC QUINASE INHIBITORS | |
IN2015DN00127A (en) | ||
CR20130539A (en) | TRIAZOLOPIRIDINS | |
MX2013002784A (en) | Fused heteroaryls and their uses. | |
UY34158A (en) | HERBICIDE COMPOSITION | |
HK1198365A1 (en) | Imidazopyridine compounds, compositions and methods of use | |
UY34016A (en) | NEW USE OF ACLIDINIO | |
IN2012DE02933A (en) | ||
UY34099A (en) | ? COMPOSITION OF COALESCENCE AGENTS ?. | |
UY34449A (en) | CLEANING COMPOSITION | |
EP2736338A4 (en) | FUSED TRICYCLIC COMPOUNDS AS mTOR INHIBITORS | |
BR112015000468A2 (en) | detergent composition | |
UY33996A (en) | SOLID PREPARATION | |
IN2011KO00551A (en) | ||
UA72478U (en) | Use of polentar as frigoprotector | |
AU336924S (en) | Hasp | |
TN2011000420A1 (en) | طريقة علمية لمقاومة التصحر وتخصيب الصحراء |